Full Breakdown
UK-US Pharmaceutical Deal Projected to Cause 229,000 Excess Deaths
7/5/2026, 12:58:31 AM
Deal Overview and Core Provisions
On 1 December, Prime Minister Keir Starmer and U.S. President Donald Trump signed a three-year pharmaceutical pact. US will waive tariffs on UK pharmaceutical and medical-technology exports until Jan 2029. The UK will raise NHS spending on new U.S. medicines from 0.3 % of GDP in 2026 to at least 0.6 % by 2036, lifting the medicines share of the NHS budget from about 10 % to 12 %.
Background and Policy Context
The deal was promoted as a landmark step toward a global medicines system that spurs innovation. A UK policy paper cited interest in new medicines, and Science Minister Patrick Vallance said the extra funding would come from the Department of Health and Social Care, not the Treasury.
Financial Impact and Projected Health Outcomes
BMJ modelling estimates the NHS will need an extra £1.3 billion a year by 2028, rising to £8.8 billion by 2036 – a total of £44.7 billion. Each £1 billion diverted adds £118 million to adult social-care costs. The analysis predicts roughly 229 000 excess deaths by 2036, exceeding the 137 000 COVID-19 deaths recorded in the UK (Mar 2020–Jun 2022). Including indirect effects raises the estimate to about 291 000 deaths.
Official Statements & Government Response
The UK government says the pact expands patient access to “life-changing new medicines” and will boost the national life-sciences sector. Vallance highlighted the zero-tariff benefit as a first for Britain. The United States described the deal as a joint effort to develop a global medicines system.
Criticism and Opposition
Professor Samuel Cross warned the deal “benefits pharmaceutical companies and comes at a cost of NHS patients.” Campaigner Tim Bierley called it a “wrecking ball” to health and the economy and noted lack of parliamentary scrutiny. Cross added that diverting NHS funds to new medicines will cut resources for cardiovascular, respiratory, gastrointestinal and cancer care.
Verbatim Quotes
- “life-changing new medicines that they previously would have been denied” — Patrick Vallance, Science Minister, UK
- “There’s really no way to sugar-coat that. The numbers speak for themselves,” — Samuel Cross, Professor of Pharmacology and Therapeutics, University of Liverpool
- “Tim Bierley, campaigner at the UK action group Global Justice Now, said: “This latest research adds to the overwhelming evidence that the Trump medicines deal risks taking a wrecking ball to our health and our economy.” — Tim Bierley, Campaigner, Global Justice Now
- “Even if we restrict attention to the direct effect of reductions in available NHS expenditure, by 2036 this deal is likely to result in roughly 229,000 excess deaths – more than during the COVID-19 pandemic between March 2020 and June 2022 (137,000).” — BMJ report authors
- “If the funds are used to pay for new medicines, we will lose positive health outcomes elsewhere, and that is as simple as that,” — Samuel Cross
What’s Next
Opponents demand an impact assessment and parliamentary review before the 2036 spending target is reached. The next prime minister may need to renegotiate the pact to protect NHS resources and avoid the projected mortality increase.
